Physician

Jeffrey Scott Brackeen, M.D.

According to 2025 Medicare claims, Jeffrey Brackeen, M.D. (NPI: 1922290592) practices dermatology in the Lubbock, TX market, with the plurality of this provider's patient population coming from Lubbock, TX. This provider's primary affiliated billing organization is SKIN CANCER INSTITUTE PLLC (NPI: 1922463959; TIN: 475071248) and primary practice location at 79414-4877.

Brackeen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 994 traditional Medicare patients, billed 14,372 HCPCS/CPT codes, and received $310,619 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,294 prescription claims across 432 beneficiaries totaling $840,088 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 69 records totaling $1,236. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $29,579 to $310,619. Similarly, Part D prescription costs have moved sharply higher in recent years, from $9,682 to $840,088. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	106	482	$29,579
2017	342	1,787	$111,017
2018	510	12,393	$158,670
2019	551	20,486	$221,391
2020	620	14,694	$209,303
2021	692	17,488	$204,458
2022	793	16,416	$234,569
2023	903	17,902	$275,873
2024	994	14,372	$310,619

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	162	$9,682
2016	69	162	$16,106
2017	194	468	$36,909
2018	246	667	$79,928
2019	287	876	$201,997
2020	321	939	$364,972
2021	329	955	$531,538
2022	361	1,028	$695,335
2023	403	1,132	$755,246
2024	432	1,294	$840,088

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	185	251	$84
17110	Destruction of skin growth, 1-14 growths	196	216	$80
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	699	925	$60
17000	Destruction of precancer skin growth, 1 growth	502	656	$40
17003	Destruction of precancer skin growth, 2-14 growths	415	2,498	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Skyrizi Pen	Risankizumab-Rzaa	19	1,484	$399,944
Humira Pen	Adalimumab	14	392	$95,066
Taltz Autoinjector	Ixekizumab	12	336	$85,478
Dupixent Pen	Dupilumab	14	452	$58,106
Opzelura	Ruxolitinib Phosphate	13	420	$25,909

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	69	$1,236	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Scott Brackeen, M.D.?

Tedicare shows public-source Medicare data for Jeffrey Scott Brackeen, M.D. (NPI 1922290592), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Scott Brackeen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jeffrey Scott Brackeen, M.D.?

Jeffrey Scott Brackeen, M.D. is linked to SKIN CANCER INSTITUTE PLLC (billing NPI 1922463959) in the available physician profile data.

Does Jeffrey Scott Brackeen, M.D. have Open Payments data?

Jeffrey Scott Brackeen, M.D. has 69 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.